Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | The future of CLL treatment

Michael Hallek • 4 Dec 2015
ASH 2015
Chronic Lymphocytic Leukemia

Michael Hallek, MD from the University of Cologne, Cologne, Germany, discusses the novel therapies being presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL, and how these impact the treatment landscape in chronic lymphocytic leukemia (CLL).

More from Michael Hallek

2:24
BCL-2 frontline therapy in CLL
Michael Hallek • 25 Aug 2020
3:53
Updates from the German CLL Study Group
Michael Hallek • 28 Aug 2020
3:02
Treating highly relapsed/refractory CLL
Michael Hallek • 27 Aug 2020
2:32
Value of MRD measurement in CLL
Michael Hallek • 27 Aug 2020

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals